STAT+: Pharmalittle: UCB selling a Chinese business, Tome layoffs, and more
Happy Monday, Pharmalittle family. Adam Feuerstein here, once again filling in for Ed. I have…
Category: STAT+
STAT+: Biden administration’s $3.2 billion antiviral pandemic plan is fizzling out
NEW YORK — Sixteen floors above Central Park, Kris White keeps his gentler pathogens behind…
STAT+: Tome Biosciences files notice to lay off nearly entire staff
High-profile gene editing startup Tome Biosciences said in a legal filing Friday that it will…
STAT+: U.S. agency slaps down a J&J plan to switch payments for 340B hospitals
A U.S. government agency said that a planned move by Johnson & Johnson to alter…
STAT+: Pharmalittle: We’re reading about AstraZeneca threatening the U.K., mpox vaccine distribution, and more
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Takeaways from the DNC on the health care fights ahead
WASHINGTON — The Democrats were not subtle this week about what their health care priorities are…
STAT+: AI in medicine: A national registry could help increase transparency, experts say
The use of artificial intelligence in hospitals is ramping up so fast — and with…
STAT+: Tome Biosciences, once a high-flying gene-editing startup, is floundering
Buzzy gene-editing startup Tome Biosciences is floundering, just nine months after launching with $213 million…
STAT+: Pharmalittle: We’re reading about a negative U.K. review of Leqembi, Bavarian Nordic’s strong earnings, and more
Good morning, Pharmalittle fans! Adam Feuerstein here, filling in for Ed. I drink my morning…
STAT+: U.K.’s cost-effectiveness agency gives negative review of Alzheimer’s drug Leqembi
LONDON — Leqembi, the Alzheimer’s treatment from Eisai and Biogen, has hit another roadblock reaching…
STAT+: Digital therapeutics pioneer Pear’s treatments get a second life, a year after bankruptcy
Over a year after Pear Therapeutics filed for bankruptcy and shut down, its smartphone apps…
STAT+: Gene therapy pioneer Jim Wilson believes he can commercialize rare-disease drugs in a tough climate
If you’d told Jim Wilson three years ago that he’d be stepping down as director…
STAT+: Pharmalittle: We’re reading about obesity drugs and suicidal thoughts, a FDA official’s conflicts, and more
Hello, everyone, and how are you today? We are doing just fine, thank you, especially…
STAT+: Federal judge blocks noncompete ban, and FTC considers appeal
A federal judge in Texas appointed by former President Donald Trump has officially spiked the…
STAT+: Congressional probe questions clinical trials run in China, citing Army involvement
A House committee is investigating whether brand drug companies are collaborating with the Chinese military…
STAT+: Pharmalittle: We’re reading about Zepbound trial results, an Alnylam heart drug, and more
Rise and shine, everyone, another busy day is on the way. We can tell because…
STAT+: Lilly’s Zepbound slashed risk of developing diabetes
Eli Lilly’s obesity drug Zepbound significantly cut the risk of developing type 2 diabetes, showing…
STAT+: Q&A: How the FDA could use AI for drug and device safety surveillance
The Food and Drug Administration’s responsibilities don’t end when a drug hits the market after…
STAT+: What to know about Alnylam’s upcoming readout on its heart drug
Next week, the biopharma world will see eagerly awaited results from a trial that could…
STAT+: Another suit filed against FDA over lab-developed test rule
A group representing molecular pathologists sued the Food and Drug Administration on Monday over its…
STAT+: Democratic platform favors slate of smaller goals over a health overhaul
WASHINGTON — Gone are the days when Democrats bickered over wholesale reform of the American…
STAT+: Pharmalittle: We’re reading about FTC scrutiny of a Novo deal, a Genentech reorganization, and more
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: AI drug firm Recursion moves from survival to industry domination
SALT LAKE CITY — On paper, Recursion Pharmaceuticals shouldn’t have worked. The company — or, at…
STAT+: Peter Orszag wants the FTC and DOJ to stop challenging health care mergers
Peter Orszag was instrumental in crafting the Affordable Care Act. Now, he wants federal antitrust…
STAT+: Will the FTC challenge a deal that would give Novo Nordisk control of some Catalent plants?
As the Federal Trade Commission scrutinizes the pharmaceutical industry, there is growing debate about whether…
STAT+: Rick Doblin, ‘unleashed,’ blasts FDA over Lykos drug rejection and turns to global push for MDMA therapy
It’s been a hard week for the psychedelics pioneer Rick Doblin. First, the Food and…
Opinion: STAT+: What the newly released Medicare prices for 10 drugs do and don’t tell us
For many of us, Thursday was Health-Policy-Wonk Festivus. The Centers for Medicare & Medicaid Services…
STAT+: Pharmalittle: We’re reading about a Covid-flu shot setback, mpox vaccine supplies, and more
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Pfizer and BioNTech effort to develop Covid-influenza combination vaccine sees setback
Pfizer and BioNTech said Friday that their combined mRNA vaccine candidate against influenza and Covid-19…
.jpg)
STAT+: UnitedHealthcare’s latest contract dispute, this time with Trinity Health, leaves thousands out-of-network
A widespread, monthslong contract dispute between UnitedHealthcare and Trinity Health has created a confusing patchwork…
STAT+: What do Biden’s drug price comparisons reveal? Not much
WASHINGTON — The White House is touting just how much its new Medicare negotiation process…
STAT+: Lykos Therapeutics cuts 75% of staff after FDA rejects MDMA-assisted therapy
Lykos Therapeutics, whose MDMA-assisted psychotherapy for post-traumatic stress disorder was rejected late last week by…
STAT+: Boston’s lab market is in as rough shape
When demand for office space cratered during the Covid-19 pandemic, many developers in the Boston…
STAT+: The business of CRISPR’d medicine: Not great
This is the online edition of Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can…
STAT+: Pharmalittle: We’re reading about Medicare drug savings, Lilly warning doctors, and more
Top of the morning to you, and a fine one it is. The skies are…
STAT+: Medicare announces drug prices for historic first round of negotiations
WASHINGTON — The day drug makers dreaded has finally arrived. Medicare officials on Thursday unveiled…
STAT+: Gilead wins U.S. approval for drug to treat autoimmune liver disease
The Food and Drug Administration on Wednesday approved a new treatment for primary biliary cholangitis,…
STAT+: Eli Lilly’s billions: Can the world’s most valuable pharma company keep inventing drugs at this pace?
On Tuesday, Eli Lilly unveiled a towering 346,000-square-foot laboratory in Boston’s Seaport District, a building…
STAT+: Pharmalittle: We’re reading about an AstraZeneca U.K. vaccine plant, Medicare premiums, and more
Hello, everyone, and how are you today? We are doing just fine, thank you, especially…
STAT+: Grail announces layoffs as it looks to push forward blood-based cancer detection test
Cancer detection firm Grail announced sizable workforce cuts on Tuesday in a bid to save…
Illumina lays out plan to boost growth by helping scientists interpret sequencing data
SAN DIEGO — The unwinding of Illumina’s ill-fated acquisition of Grail earlier this year left…
STAT+: Acelyrin announces layoffs, strategy shift after late-stage trial results for anti-inflammatory drug
Acelyrin, a California biotech focused on immunology and inflammatory disease, announced Tuesday that its experimental…
STAT+: Pharmalittle: We’re reading about Novartis losing bid to block a generic, pharma deals, and more
Rise and shine, everyone, another busy day is on the way. Our mascots, for instance,…
STAT+: Otsuka starts selling depression digital therapeutic, expects to lose money on it
Otsuka Pharmaceutical has started selling Rejoyn, its Food and Drug Administration cleared prescription app that…
STAT+: Meet the billionaire media mogul who’s taking on the food industry
WASHINGTON — The idea for Todd Wagner’s new advocacy organization FoodFight USA, he says, came…
STAT+: Why U.S. health care cybersecurity laws are better at protecting a corpse’s privacy than patients’ lives
Two days into a cyberattack on his hospital system, Nate Couture reached the end of…
STAT+: Pharmalittle: We’re reading about FDA rejecting MDMA; a nasal spray for allergic reactions, and more
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Pharmalittle: We’re reading about a California bill to restrain PBMs, a U.K. trade group scolding Novo, and more
And so, another working week will soon draw to a close. Not a moment too…
STAT+: A bespoke genetic therapy is helping Susannah. Can similar drugs be made at scale for other rare diseases?
Will it work? It was the question everyone around Susannah Rosen kept asking. Since infancy,…
STAT+: Medicare paid substantially more for J&J’s Stelara when it was covered under Part D than under Part B
A popular biologic medicine used to combat autoimmune diseases cost Medicare and its beneficiaries considerably…